EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseKohortenstudieOpen Access

SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis

Sai Harisha Rajanala, Anna Plym, Jane B Vaselkiv, Ericka M Ebot, Konstantina Matsoukas, Zhike Lin, Goutam Chakraborty, Sarah C Markt, Kathryn L Penney, Gwo-Shu M Lee, Lorelei A Mucci, Philip W Kantoff und 1 weitere

Carcinogenesis · 2024

DOI: 10.1093/carcin/bgad075 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Carcinogenesis, 2024. Verfasst von Sai Harisha Rajanala und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Organic Anion Transporters. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Department of Defense, Cancer Center Support.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Solute carrier organic anion (SLCO) transporters (OATP transporters) are involved in cellular uptake of drugs and hormones. Germline variants in SLCO1B3 and SLCO2B1 have been implicated in prostate cancer progression and therapy response, including to androgen deprivation and statin medications, but results have appeared heterogeneous. We conducted a cohort study of five single-nucleotide polymorphisms (SNPs) in SLCO1B3 and SLCO2B1 with prior evidence among 3208 men with prostate cancer who participated in the Health Professionals Follow-up Study or the Physicians’ Health Study, following participants prospectively after diagnosis over 32 years (median, 14 years) for development of metastases and cancer-specific death (lethal disease, 382 events). Results were suggestive of, but not conclusive for, associations between some SNPs and lethal disease and differences by androgen deprivation and statin use. All candidate SNPs were associated with SLCO mRNA expression in tumor-adjacent prostate tissue. We also conducted a systematic review and harmonized estimates for a dose-response meta-analysis of all available data, including 9 further studies, for a total of 5598 patients and 1473 clinical events. The A allele of the exonic SNP rs12422149 (14% prevalence), which leads to lower cellular testosterone precursor uptake via SLCO2B1, was associated with lower rates of prostate cancer progression (hazard ratio per A allele, 0.80; 95% confidence interval, 0.69–0.93), with little heterogeneity between studies (I2, 0.27). Collectively, the totality of evidence suggests a strong association between inherited genetic variation in SLCO2B1 and prostate cancer prognosis, with potential clinical use in risk stratification related to androgen deprivation therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsHydroxymethylglutaryl-CoA Reductase InhibitorsOrganic Anion TransportersMaleHumansAndrogen AntagonistsAndrogensFollow-Up StudiesCohort StudiesProspective StudiesGenotypeSolute Carrier Organic Anion Transporter Family Member 1B3

Substanzen

Androgen AntagonistsAndrogensHydroxymethylglutaryl-CoA Reductase InhibitorsOrganic Anion TransportersSLCO2B1 protein, humanSLCO1B3 protein, humanSolute Carrier Organic Anion Transporter Family Member 1B3

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Department of Urology, Brigham and Women's Hospital, Boston, MA, USA.
  • Technology Division, Library Services, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Urology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

ORCID-Profile: Konrad H Stopsack

Förderung

  • NCI NIH HHS
  • Department of Defense
  • Cancer Center Support
  • National Cancer Institute

Zitieren

APA

Rajanala, S. H., Plym, A., Vaselkiv, J. B., Ebot, E. M., Matsoukas, K., Lin, Z., Chakraborty, G., Markt, S. C., Penney, K. L., Lee, G. M., Mucci, L. A., Kantoff, P. W., & Stopsack, K. H. (2024). SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis. Carcinogenesis. https://doi.org/10.1093/carcin/bgad075

Vancouver

Rajanala SH, Plym A, Vaselkiv JB, Ebot EM, Matsoukas K, Lin Z, et al. SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis. Carcinogenesis. 2024. doi:10.1093/carcin/bgad075

BibTeX
@article{Rajanala2024,
  author = {Rajanala, Sai Harisha and Plym, Anna and Vaselkiv, Jane B and Ebot, Ericka M and Matsoukas, Konstantina and Lin, Zhike and Chakraborty, Goutam and Markt, Sarah C and Penney, Kathryn L and Lee, Gwo-Shu M and Mucci, Lorelei A and Kantoff, Philip W and Stopsack, Konrad H},
  title = {SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis},
  journal = {Carcinogenesis},
  year = {2024},
  doi = {10.1093/carcin/bgad075}
}
Kostenlos starten →